Altre lingue Amgen Inc. Sao Paulo

Azioni

AMGN34

BRAMGNBDR004

Mercato chiuso - Sao Paulo Altri mercati azionari 16:25:03 13/06/2024			Variaz. 5gg	Var. 1 gen.
57,22 ^BRL	-1,87%		-1,31%	+14,55%

14/06	Amgen Inc. annuncia che la Food and Drug Administration statunitense approva Blincyto	CI
14/06	Aggiornamento settoriale: titoli del settore sanitario più deboli venerdì pomeriggio	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	14/06
Amgen : Continues to Propel BiTE® Technology Innovation	14/06
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	14/06
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE	14/06
Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto	14/06
Sector Update: Health Care Stocks Softer Friday Afternoon	14/06
Wall Street finit contrastée, nouveaux records pour Nasdaq et S&P 500	13/06
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%	13/06
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024	12/06
Amgen : Leaders Hail Southern California’s Emergence as Biotech Innovation Hub	11/06
Updates On Aflibercept Biosimilar Approvals And BPCIA Litigation	11/06
FDA Approves Amgen's BKEMV, The First Eculizumab Biosimilar	11/06
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	10/06
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE	06/06
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE	05/06
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints	05/06
Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD	05/06
Amgen's drug meets main goal in late-stage study for rare disease	05/06
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)	05/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Amgen Inc. Sao Paulo

Azioni

AMGN34

BRAMGNBDR004

Altre lingue

Filtri